SG10201804000TA - Compositions for the treatment of rheumatoid arthritis and methods of using same - Google Patents

Compositions for the treatment of rheumatoid arthritis and methods of using same

Info

Publication number
SG10201804000TA
SG10201804000TA SG10201804000TA SG10201804000TA SG10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA SG 10201804000T A SG10201804000T A SG 10201804000TA
Authority
SG
Singapore
Prior art keywords
methods
rheumatoid arthritis
compositions
treatment
same
Prior art date
Application number
SG10201804000TA
Inventor
Xiaohong Huang
Martine Jasson
Vanessa Marks
Allen Radin
Chungpeng Fan
Hoogstraten Hubert Van
Stefano Fiore
Adelsberg Janet Van
Mark Genovese
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG10201804000TA publication Critical patent/SG10201804000TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody that specifically binds 5 human interleukin-6 receptor (hIL-6R).
SG10201804000TA 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same SG10201804000TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907796P 2013-11-22 2013-11-22
US201462008787P 2014-06-06 2014-06-06
EP14306366 2014-09-05

Publications (1)

Publication Number Publication Date
SG10201804000TA true SG10201804000TA (en) 2018-07-30

Family

ID=51518724

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201804000TA SG10201804000TA (en) 2013-11-22 2014-11-21 Compositions for the treatment of rheumatoid arthritis and methods of using same

Country Status (11)

Country Link
US (1) US20160280782A1 (en)
EP (2) EP3071230B1 (en)
JP (3) JP6657089B2 (en)
KR (3) KR20230155586A (en)
CN (1) CN106413748A (en)
AU (2) AU2014352801B2 (en)
CA (1) CA2930615C (en)
MX (2) MX2016006595A (en)
PL (1) PL3071230T3 (en)
SG (1) SG10201804000TA (en)
WO (1) WO2015077582A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
JP7272794B2 (en) 2015-11-03 2023-05-12 サノフィ・バイオテクノロジー Compositions Comprising IL6R Antibodies and Methods of Using The Same for Treatment of Uveitis and Macular Edema
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
JP7166925B2 (en) * 2016-03-07 2022-11-08 サノフィ・バイオテクノロジー Compositions and methods for treating rheumatoid arthritis
CA3084757A1 (en) 2017-12-07 2019-06-13 Fujimori Kogyo Co., Ltd. Port-equipped bag and cap-equipped bag
MA53481A (en) * 2018-08-29 2021-07-07 Regeneron Pharma METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
SG11202107735SA (en) 2019-01-31 2021-08-30 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
MA55760A (en) * 2019-04-24 2022-03-02 Regeneron Pharma METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS
JP7373958B2 (en) 2019-09-27 2023-11-06 株式会社日立製作所 Analysis system and method
KR20210040735A (en) 2019-10-05 2021-04-14 양수현 Compartment ceiling a clothes horse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
TWI589299B (en) * 2011-10-11 2017-07-01 再生元醫藥公司 Compositions for the treatment of rheumatoid arthritis and methods of using same
PT3071230T (en) * 2013-11-22 2020-06-26 Regeneron Pharma Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
CA2930615A1 (en) 2015-05-28
JP2016539125A (en) 2016-12-15
EP3770173A1 (en) 2021-01-27
MX2020011993A (en) 2021-01-29
AU2020223706A1 (en) 2020-09-10
AU2014352801B2 (en) 2020-05-28
US20160280782A1 (en) 2016-09-29
EP3071230B1 (en) 2020-04-08
KR20160079121A (en) 2016-07-05
KR20230155586A (en) 2023-11-10
PL3071230T3 (en) 2020-09-21
EP3071230A1 (en) 2016-09-28
CN106413748A (en) 2017-02-15
JP6657089B2 (en) 2020-03-04
WO2015077582A1 (en) 2015-05-28
KR20220056254A (en) 2022-05-04
CA2930615C (en) 2023-04-04
AU2020223706B2 (en) 2024-04-18
JP2022033891A (en) 2022-03-02
MX2016006595A (en) 2016-09-06
AU2014352801A1 (en) 2016-06-23
JP2024026223A (en) 2024-02-28

Similar Documents

Publication Publication Date Title
MX2020011993A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same.
MY191169A (en) Anti-fcrh5 antibodies
MX2021015309A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same.
MX2023000889A (en) Bcma antibodies and use of same to treat cancer and immunological disorders.
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MX2020008436A (en) ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE.
NZ760841A (en) Agonist antibodies that bind human cd137 and uses thereof
MX342810B (en) Anti-il-6 receptor antibodies and methods of use.
PH12015502788A1 (en) Antibody formulations and methods
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
MX2015013901A (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof.
MX2015012326A (en) Anti-crth2 antibodies and their use.
MX2022011972A (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same.
MX2021010472A (en) Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics.
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
MX2014013678A (en) Agents for influenza neutralization.
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
EA201891527A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF CANCER ETHESIS
EA201891528A1 (en) COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF GASTRIC CANCER
MX2019014714A (en) Anti-trkb antibodies.
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
MX2018009218A (en) Cgrp antibodies and uses thereof.